Clinical trials: Chemotherapy, Concurrent
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055887
- Testing
- carboplatin, cisplatin, efaproxiral
- Where
- 22 sites in United States, Belgium and 2 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Advanced Oral and Maxillofacial Malignant Tumors
rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , or combination with surgery for treatment of advanced oral…
- Trial name
- rAd-p53 (NCT00902083)
- Testing
- p53 gene with surgery, surgery, p53 with chemotherapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Emphysema
TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)
This 2 arm study will investigate the efficacy, safety and tolerability of RAR Gamma versus placebo in ex-smokers with moderate or severe emphysema treated with optimal COPD therapy.
- Trial name
- NCT00413205
- Testing
- RAR Gamma
- Where
- 64 sites in United States, Bulgaria and 10 more
- Volunteers
- 491 people
- Sponsor
- Hoffmann-La Roche
Nasopharyngeal Neoplasms
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
Primary objective: To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.
- Trial name
- NCT00436293
- Testing
- Docetaxel, Cisplatin
- Where
- Hong Kong
- Volunteers
- 61 people
- Sponsor
- Sanofi
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Non-Small Cell Lung Cancer (NSCLC)
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to test the effectiveness and safety of TTFields therapy, delivered using the NovoTTF-200T device, concomitant with pembrolizumab in subjects with metastatic NSCLC previously treated with a PD-1/PD-L1…
- Trial name
- LUNAR-4 (NCT06558799)
- Testing
- NovoTTF-200T, Pembrolizumab
- Where
- 24 sites in Austria, Czechia and 5 more
- Volunteers
- 31 people
- Sponsor
- NovoCure GmbH
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
This double-blind, placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir / Zovirax (AZT and ACV) therapy and oral AZT therapy alone, in the treatment of early symptomatic…
- Trial name
- NCT00002290
- Testing
- Zidovudine, Acyclovir
- Where
- 14 sites in United States
- Sponsor
- Glaxo Wellcome
Squamous Cell Carcinoma of the Head and Neck
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
The use of multiple drugs in a single clinical trial or as a therapeutic strategy has become common, particularly in the treatment of cancer.
- Trial name
- NCT02022098
- Testing
- Cisplatin, Radiotherapy, Debio 1143
- Where
- 19 sites in France, Switzerland
- Volunteers
- 144 people
- Sponsor
- Debiopharm International SA
Non-small Cell Lung Cancer
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus chemotherapy with concurrent radiotherapy in non-small cell lung cancer
- Trial name
- NCT02215356
- Testing
- Icotinib with concurrent radiotherapy, Chemoradiotherapy
- Where
- 26 sites in China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
The purpose of this study is to determine whether [18F]-ML-10 used in conjunction with PET imaging is effective as an imaging tool for the early detection of response of oncological tumors in the lungs,head and neck to…
- Trial name
- NCT01260480
- Testing
- [18F]-ML-10 in conjunction with PET imaging
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aposense Ltd.
Myelofibrosis, Anemia
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo.
- Trial name
- ELRISE MF (NCT07623161)
- Testing
- Elritercept
- Where
- 195 sites in United States, Argentina and 29 more
- Volunteers
- 324 people
- Sponsor
- Takeda
HIV Infections
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC.
- Trial name
- NCT00002001
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 5 sites in United States, Australia and 1 more
- Sponsor
- Glaxo Wellcome
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor…
- Trial name
- NCT04923906
- Testing
- Aumolertinib
- Where
- China
- Volunteers
- 624 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Stage III Non-small Cell Lung Cancer
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased…
- Trial name
- ARTIA-Lung (NCT05488626)
- Testing
- Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy
- Where
- United States
- Sponsor
- Varian, a Siemens Healthineers Company
Muscle Invasive Bladder Urothelial Carcinoma
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during…
- Trial name
- ARTIA-Bladder (NCT05700227)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Varian, a Siemens Healthineers Company